Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px
All >

Deals > Denmark

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Denmark, or involving organisations from Denmark.

Total search results: 326 | Ordered by Date (descending)
1 2 3 4  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Orphazyme–SEVERAL: investment, 202002 directed issue + private placement DKK745m (€100m) of 7m new + existing shares 2020-02-07
PharmAkea–Galecto Biotech: investment, 202001– merger €na with new Galecto Inc in US with operational HQ in Copenhagen ANNOUNCED 2020-01-07
VectivBio–Novo Group: investment, 202001 1st financing round totalling $35m incl Novo Holdings 2020-01-07
Integrated Biotherapeutics–Novo Group: investment, 202001 investment $3.9m in IBT Vaccines by Novo REPAIR Impact Fund 2020-01-06
Pharma Omnium–Novo Group: investment, 202001 investment €7m by Novo REPAIR Impact fund into Mutabilis 2020-01-06
CureVac–Genmab: investment, 201912 equity investment €20m by Genmab as part of strategic alliance 2019-12-19
Genmab–CureVac: mRNA-based antibody therapeutics, 201912– collab research + license agreem 5y $10m upfront using CureVac mRNA + Genmab Ab technologies 2019-12-19
Novo Group–Optimum Strategic Communications: public relations, 201911 service existent by Optimum 2019-11-26
Veloxis Pharmaceuticals–Asahi Kasei: investment, 201911– recommended cash offer DKK 8.9b ($1.3b) by Asahi Kasei Pharma Denmark A/S 2019-11-25
Dicerna Pharmaceuticals–Novo Group: investment, 201911 investment $50m by Novo in connection with r+d collab 2019-11-18
Novo Group–Dicerna Pharmaceuticals: RNAi therapeutics, 201911– collab r+d $175m upfront + milestones + investm RNAi drugs liver diseases using GalXC 2019-11-18
Disc Medicine–Novo Group: investment, 201910 financing round Series A totalling $50m incl new + lead investor Novo Holdings A/S 2019-10-29
Encycle Therapeutics–Zealand Pharma: investment, 201910 acquisition of Encycle Therapeutics for up to $80m 2019-10-22
Bavarian Nordic–GSK: vaccines, 201910 acquisition up to €796m incl €301m upfront of manufacturing + global rights to Rabipur/RabAvert + Encepur by BN 2019-10-21
Novo Group–Bluebird Bio: gene therapy, 201910–202209 collab r+d 3y utilising megaTAL technology to develop hemophilia A gene therapies 2019-10-09
Lundbeck–LeadXPro: drug discovery services, 201910– collab structural proteomics services using X-ray + cryo-EM for small molecule drug discovery 2019-10-07
Technical Univ Denmark–Inscripta: genome engineering technology, 201910 supply existent TUD NNFCB early customer Onyx Genome Engineering platform 2019-10-01
STipe Therapeutics–SEVERAL: investment, 201909 financing round Series A €20m co-led by Arix Bioscience + Novo Holdings 2019-09-30
Alder Biopharmaceuticals–Lundbeck: investment, 201909–201910 acquisition tender offer in cash + CVRs up to $1.95b net of cash 2019-09-16
Ascendis Pharma–Morgan Stanley: investor conference, 201909 supply service Ascendis presents at Morgan Stanley Global Healthcare Conference NY 2019-09-10
Genmab–Tempus: AI-based drug discovery, 201909– strateg collab multi-year r+d targets + biomarker for personalised cancer drugs 2019-09-09
Ascendis Pharma–Wells Fargo: investor conference, 201909 supply service Ascendis presents at Wells Fargo Healthcare Conference in Boston 2019-09-04
Protelux (RU)–Unibio: protein production from methane, 201908 collab existing buidling + operating plant for Uniprotein production in Russia 2019-08-28
Nanovi–SEVERAL: investment, 201908 financing round DKK19m from existing investors 2019-08-27
Genmab–SEVERAL: investment, 201907 US IPO $581.6m with 28.5m+4.275m ADSs at $17.75/ADS with 10 ADSs/share at Nasdaq Global Select Market 2019-07-22
Genmab–Blink Biomedical: therapeutic antibodies, 201907– license to use CD47 Abs in DuoBodies $2.25m upfront + up to $200m per product plus royalties 2019-07-12
IGM Biosciences–Haldor Topsøe: investment, 201907 financing round Series C totalling $102m incl existing + founding investor Haldor Topsøe Holding A/S 2019-07-08
Danaher–Cobo Technologies: protein expression analysis, 201907– collab co-marketing PIPPR platform with SWATH Acquisition + Sciex TripleTOF 6600 2019-07-05
Sanifit–Lundbeck: investment, 201906 financing round Series D totalling €55.2m incl existing + co-investor Lundbeckfonden Ventures 2019-06-26
Spero Therapeutics–Novo Group: investment, 201906– direct offering common stock up to $10m in two tranches of $5m to Novo REPAIR Fund 2019-06-13
JnJ–Genmab: antibody cancer drug, 201906– collab + excl ww license + option agreem for HexaBody-CD38 monoclonal antibody 2019-06-11
Oxford BioMedica–Novo Group: investment, 201905–201906 investment £45.3m + optional £8.2m with 6.6m+1.2m new shares at £6.9/share 2019-05-28
Symphogen–SEVERAL: investment, 201905– capital increase up to DKK572m incl DKK182m debt conversion from existing shareholders 2019-05-15
Therachon–Novo Group: investment, 201905 existing investor Novo Holdings 2019-05-08
Abide Therapeutics–Lundbeck: investment, 201905 acquisition $250m upfront + $150m milestones of Abide by Lundbeck 2019-05-06
United States (govt)–Cobo Technologies: genome editing, 201904– collab Cobo beomes member of NIST Genome Editing Consortium 2019-04-15
Gilead–Novo Group: drug development, 201904– collab clinical research for NASH combining semaglutide + cilofexor + firsocostat Novo Nordisk 2019-04-12
Chr Hansen–Lonza: live biotherapeutics, 201904– collab establishment 50/50 joint venture for developing + manufacturing microbiome treatments 2019-04-02
Lundbeck–Enamine: chemical compound libraries, 201903– supply expansion discovery chemistry services by Enamine 2019-03-26
Verona Pharma–Novo Group: investment, 201903 existent investment Novo Holdings owns 11.76% shareholding in Verona Pharma plc 2019-03-21
Biogen–Fujifilm: biologics contract manfuacturing, 201903– supply manufacturing of biologicals for Biogen incl Tysabri 2019-03-12
Biogen–Fujifilm: investment, 201903–201908 acquisition up to $890m in cash of Biogen’s Biologics Manufacturing Site in Hillerød Denmark 2019-03-12
Snipr Biome–Life Sciences Partners: investment, 201903 financing round Series A totalling $50m incl co-lead investor LSP 2019-03-11
Snipr Biome–Lundbeck: investment, 201903 financing round Series A totalling $50m incl existing + co-lead investor Lundbeckfonden Emerge 2019-03-11
Snipr Biome–North-East Family Office: investment, 201903 financing round Series A totalling $50m incl co-investor North-East Family Office 2019-03-11
Snipr Biome–SEVERAL: investment, 201903 financing round Series A $50m co-led by Lundbeckfonden Emerge + Life Sciences Partners 2019-03-11
Snipr Biome–Wellington Partners: investment, 201903 financing round Series A totalling $50m incl co-investor Wellington Partners 2019-03-11
Ascendis Pharma–SEVERAL: investment, 201903– public offering $400m+$60m ADSs 2019-03-04
Samplix–EU (govt): grant, 201901– Horizon 2020 SME Instrument Program Grant €1.9m 2019-01-10
Minervax–Novo Group: investment, 2018 investment €3.6m by Novo REPAIR Impact Fund 2018-12-31
Procarta Biosystems–Novo Group: investment, 2018 investment €1.5m by Novo REPAIR Impact Fund 2018-12-31
Leo Pharma–Evotec: drug discovery services, 201812– collab €na integrated drug discovery to generate leads against innovative dermatic targets 2018-12-04
BridgeBio–Leo Pharma: investment, 201811 acquisition minority stake in PellePharm Inc plus r+d funding + plus option to aquire PellePharm 2018-11-20
Symphogen–Thermo Fisher: mass spectrometer, 201810 supply Q Exactive Plus Orbitrap LC-MS/MS with BioPharma Option for biopharma QC 2018-10-29
Thermo Fisher–Symphogen: mass spectrometry, 201810– collab developm biopharma QC workflows using Q Exactive Plus Orbitrap LC-MS/MS system 2018-10-29
Galecto Biotech–BPCE: investment, 201810 financing round Series C totalling €79m incl new + co-investor Seventure Partners 2018-10-26
Galecto Biotech–OrbiMed: investment, 201810 financing round Series C totalling $79m incl new + co-lead investor OrbiMed 2018-10-26
Galecto Biotech–SEVERAL: investment, 201810 financing round Series C €79m co-led by Ysios Capital + OrbiMed 2018-10-26
Galecto Biotech–Ysios Capital: investment, 201810 financing round Series C totalling $79m incl new + co-lead investor Ysios Capital 2018-10-26
Milestone Pharmaceuticals–Novo Group: investment, 201810 financing round private totalling $80m incl existing + co-investor Novo Holdings A/S 2018-10-25
Rgenix–Novo Group: investment, 201810 financing round Series C totalling $40m incl existing + co-investor Novo Holdings AS 2018-10-09
Entasis Therapeutics–Novo Group: investment, 201809 IPO totalling $75m on Nasdaq incl $10m investment by Novo REPAIR Impact Fund 2018-09-25
Fluidigm–Visiopharm: image analysis software, 201809– collab co-marketing of Visiopharm s/w with Hyperion Imaging System 2018-09-10
RSP Systems–SEVERAL: investment, 201809 financing round Series B 2nd closing €3.85m incl new investor Trumpf Venture GmbH 2018-09-10
RSP Systems–Trumpf: investment, 201809 financing round Series B 2nd closing totalling €3.85m incl new investor Trumpf Venture GmbH 2018-09-10
Polyphor–Novo Group: investment, 201809 capital increase CHF6.8m with 179k shares at CHF38/share sold to Novo REPAIR Impact Fund 2018-09-06
Polyphor–Novo Group: investment, 201809– project-based + royalty-bearing investment up to CHF4.7m based on milestones in OMPTA program by Novo REPAIR 2018-09-06
Visiopharm–ATP (DK): investment, 201808 financing round totalling DKK100m (€13.3m) incl DKK45m from new + lead investor ATP 2018-08-24
Visiopharm–CL David Foundation: investment, 201808 financing round totalling DKK100m (€13.3m) incl DKK15m from new investor CL David Foundation 2018-08-24
Visiopharm–Denmark (govt): investment, 201808 financing round totalling DKK100m (€13.3m) incl DKK20m from new investor Danish Growth Fund 2018-08-24
Visiopharm–Northcap Venture Partners: investment, 201808 financing round totalling DKK100m (€13.3m) incl DKK15m from existing investor Northcap 2018-08-24
Visiopharm–SEVERAL: investment, 201808 financing round DKK100m (€13.3m) led by new investor ATP 2018-08-24
Novo Group–Evotec: drug discovery services, 201808– collab €na strategic alliance r+d small molecule drugs for diabetes + obesity Novo Nordisk 2018-08-22
Bavarian Nordic–PCI Biotech: PCI technology, 201808– collab research preclinical evaluation of integration of technologies from both companies 2018-08-20
Ziylo–Novo Group: investment, 201808 acquisition 100% for up to $800m in upfront + milestone payments by Novo Nordisk 2018-08-17
Bavarian Nordic–EU (govt): credit, 201808– EIB loan €30m to support construction + validation of vaccine manufacturing facility 2018-08-09
ReViral–Novo Group: investment, 201808 financing round Series B totalling $55m incl new + co-lead investor Novo Ventures 2018-08-01
Bayer–Leo Pharma: investment, 201807–201907 acquisition of global prescription dermatology business of Bayer 2018-07-31
Genmab–Immatics: cancer immunotherapy, 201807– researc collab + excl license to targets for biospecific I-O drugs $54m upfront + $550m milestones 2018-07-12
NBE Therapeutics–Novo Group: investment, 201806 financing round Series B CHF20m extension by Novo Holdings bringing total Series B to CHF40m 2018-06-28
RSP Systems–SEVERAL: investment, 201806 financing round Series B first closing €6.5m incl family offices + private investors 2018-06-11
Orphazyme–Centogene: biomarker discovery, 201805– collab service biomarkers for Gaucher disease clinical trial monitoring 2018-05-23
Novo Group–BioLamina: cell culture technology, 201805– collab using BioLaminins rec hum laminin cell culture matrices for cell therapies Novo Nordisk 2018-05-16
NMD Pharma–ABP (NL): investment, 201803 financing round Series A totalling €38m incl new + lead investor Inkef Capital 2018-03-23
NMD Pharma–Lundbeck: investment, 201803 financing round Series A totalling €38m incl existing + co-investor Lundbeckfonden Emerge 2018-03-23
NMD Pharma–Novo Group: investment, 201803 financing round Series A totalling €38m incl existing + co-investor Novo Seeds 2018-03-23
NMD Pharma–Roche: investment, 201803 financing round Series A totalling €38m incl new + co-investor Roche Venture Fund 2018-03-23
NMD Pharma–SEVERAL: investment, 201803 financing round Series A €38m led by new investor Inkef Capital + incl RVF + Novo Seeds + Lundbeckfonden 2018-03-23
Prexton Therapeutics–Lundbeck: investment, 201803– acquisition €100m upfront + €805m developm + sales milestones ANNOUNCED 2018-03-16
Bruker–Evosep: liquid chromatography, –201802 collab product integration of timsTOF Pro MS + Evosep One LC for HT clinical proteomics 2018-02-26
Ascendis Pharma–SEVERAL: investment, 201802 public offering $225m net $210m with 3.95m ADSs at $57/ADS 2018-02-20
Ascendis Pharma–JPMorgan Chase: investor conference, 201801 supply service Ascendis presents at JP Morgan Healthcare Conference 2018 2018-01-08
Enterome–Lundbeck: investment, 201801 financing round Series D totalling €32m incl existing investor LundbeckFonden Ventures 2018-01-04
Ablynx–Novo Group: investment, 201712– acquisition unsolicited cash offer €2.6b up to €30.5/share ANNOUNCED + REJECTED 2017-12-22
Ascendis Pharma–Spark BioComm: public relations, 201712 service existent by Spark BioComm 2017-12-21
Ascendis Pharma–Westwicke Partners: public relations, 201712 service existent IR by Westwicke Partners 2017-12-21
NorthSea Therapeutics–Novo Group: investment, 201712 financing round Series A totalling €25m incl co-investor Novo Seeds 2017-12-12
AntibioTx–EU (govt): credit, 201710– EIB loan €20m to AntibioTx A/S for antibotics development 2017-10-26
Clinical Innovations–EQT: investment, 201710 acquisition by EQT Mid Market US Fund 2017-10-18
Ascendis Pharma–SEVERAL: investment, 201709 public offering $134m+20m with 3.8m+570k ADSs at $35.5/ADS 2017-09-26
1 2 3 4  next pagenext page



Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 650x65px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

» top